Behavioural Pharmacology 2011-09-01

The metabolites N-desmethylclozapine and N-desmethylolanzapine produce cross-tolerance to the discriminative stimulus of the atypical antipsychotic clozapine in C57BL/6 mice.

Jason M Wiebelhaus, Kevin A Webster, Herbert Y Meltzer, Joseph H Porter

Index: Behav. Pharmacol. 22(5-6) , 458-67, (2011)

Full Text: HTML

Abstract

It has been previously shown that cross-tolerance to the discriminative stimulus properties of clozapine can be demonstrated with the drug discrimination paradigm. This study examined the ability of N-desmethylclozapine and N-desmethylolanzapine (metabolites of the atypical antipsychotic drugs clozapine and olanzapine, respectively) to induce cross-tolerance to the discriminative stimulus effects of clozapine. After C57BL/6 mice were trained to reliably discriminate 2.5 mg/kg clozapine from vehicle, a clozapine generalization curve was generated. Next, training was suspended and the mice received a maintenance dosing regimen in which they were injected twice daily with 10 mg/kg N-desmethylclozapine for 10 days. Then a second clozapine generalization curve was generated. This was followed by a 10-day washout period during which the mice did not receive drug injections or discrimination training. Finally, a third clozapine generalization curve was generated. These same procedures were followed for N-desmethylolanzapine (10 mg/kg twice daily during maintenance dosing). Both N-desmethylclozapine and N-desmethylolanzapine produced significant rightward shifts in the clozapine generalization curve indicating cross-tolerance between N-desmethylclozapine and clozapine and between N-desmethylolanzapine and clozapine. After a washout period with no training or drug administration this cross-tolerance effect was lost for both metabolites. This cross-tolerance drug discrimination procedure demonstrated in-vivo similarities between these two metabolites and clozapine and suggests that common underlying pharmacological mechanisms were responsible for the cross-tolerance that was observed. These findings also demonstrated that this procedure may be useful for identifying drugs with therapeutic efficacy similar to the atypical antipsychotic clozapine under repeated dosing conditions.


Related Compounds

Related Articles:

Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate.

2010-11-01

[Leg. Med. (Tokyo.) 12(6) , 300-4, (2010)]

Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.

2005-09-05

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2) , 167-71, (2005)]

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.

2004-12-01

[Brain Dev. 26(8) , 530-4, (2004)]

Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD.

1996-11-01

[Scand. J. Clin. Lab. Invest. 56(7) , 609-14, (1996)]

Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.

2006-07-01

[Dev. Med. Child Neurol. 48(7) , 612-5, (2006)]

More Articles...